Clinical Trial Detail

NCT ID NCT02177812
Title A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

acute myeloid leukemia

Therapies

GSK2879552

Age Groups: adult

No variant requirements are available.